Conference Track

Breast Cancer

Source: CCO Independent Conference Coverage of the 2007 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Everolimus Active in Metastatic Breast Cancer
Addition of Lapatinib to Paclitaxel Improves Efficacy in HER2-Positive Advanced Breast Cancer
Chromosome 17 Polysomy May Predict Increased Response to Trastuzumab in HER2-Negative Metastatic Breast Cancer
Combination Ixabepilone/Capecitabine Regimen Superior to Capecitabine Alone in Heavily Pretreated MBC
HER2 Dimerization Inhibitor Pertuzumab in Combination With Trastuzumab Demonstrated Efficacy in Metastatic Breast Cancer Following Trastuzumab Progression
Mathematical Modeling Predicts for Feasible Biweekly Capecitabine Dosing in Metastatic Breast Cancer
Adding Axitinib to Docetaxel Improves Response Rate and Time to Progression in Locally Advanced or Metastatic Breast Cancer
Vinflunine Plus Trastuzumab Active and Tolerable for Patients With HER2-Positive MBC
Study Demonstrated Improved Efficacy and Tolerability With nab-Paclitaxel Compared With Docetaxel in Patients With Metastatic Breast Cancer
No Significant Difference in Disease-Specific Survival Between Total Mastectomy and Breast Conserving Surgery With Radiation in Patients With Carcinoma in Situ of the Breast
Radiation and Tamoxifen Reduce Risk of Invasive Ipsilateral Breast Tumor Recurrence in Lumpectomy-Treated DCIS
Lapatinib Modestly Active in Patients With HER2-Positive Breast Cancer With CNS Metastases
Adjuvant Trastuzumab Benefit Seen in Both HER2-Positive and HER2-Negative Breast Cancers
Overall Survival Benefit Observed With Adjuvant Doxorubicin/Paclitaxel Combination Followed by Weekly Paclitaxel in High-Risk Breast Cancer
Topoisomerase II-alpha Amplification Predictive of Benefit From Anthracycline-Based Chemotherapy in HER2-Positive Breast Cancer

Expert Analysis

Breast Cancer

Faculty:
William J. Gradishar, MD, FACP Clifford A. Hudis, MD Christy Russell, MD
George W. Sledge, Jr., MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data from recent studies regarding treatment of patients with ductal carcinoma in situ
Discuss the use of chemotherapy combinations and/or novel agents in the treatment of advanced or metastatic breast cancer
Review the efficacy of several novel targeted therapies and cytotoxic therapies currently under evaluation for the treatment of metastatic breast cancer
Describe different challenges in the use of HER2 testing for patients with breast cancer
Articulate recent data concerning the use of gene expression profiling to guide treatment

CME CREDIT INFORMATION

Release Date: 08/09/07

Expiration Date: 08/08/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.